Proactiveinvestors United Kingdom Companies https://www.biotech-capital.com Proactiveinvestors United Kingdom Companies RSS feed en Sun, 25 Oct 2020 02:16:50 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) https://www.biotech-capital.com/companies/news/932278/lloyds-and-bank-peers-bt-bp-shell-and-us-tech-giants-make-for-packed-week-ahead-932278.html Lloyds and bank peers, BT, BP, Shell and US tech giants make for packed week ahead https://www.biotech-capital.com/companies/news/932278/lloyds-and-bank-peers-bt-bp-shell-and-us-tech-giants-make-for-packed-week-ahead-932278.html Fri, 23 Oct 2020 13:55:00 +0100 https://www.biotech-capital.com/companies/news/223829/lexaria-bioscience-seeing-increased-demand-for-its-dehydratech-drug-delivery-system-223829.html Lexaria Bioscience seeing increased demand for its DehydraTECH drug delivery system https://www.biotech-capital.com/companies/news/223829/lexaria-bioscience-seeing-increased-demand-for-its-dehydratech-drug-delivery-system-223829.html Fri, 23 Oct 2020 11:45:00 +0100 https://www.biotech-capital.com/companies/news/932239/sensyne-health-inks-collaboration-deal-with-bristol-myers-squibb---it-s-fourth-partnership-with-a-major-pharma-company-932239.html Sensyne Health inks collaboration deal with Bristol Myers Squibb - it's fourth partnership with a major pharma company https://www.biotech-capital.com/companies/news/932239/sensyne-health-inks-collaboration-deal-with-bristol-myers-squibb---it-s-fourth-partnership-with-a-major-pharma-company-932239.html Fri, 23 Oct 2020 10:40:00 +0100 https://www.biotech-capital.com/companies/news/215244/faron-pharma-right-in-middle-of-fight-against-cancer-and-coronavirus-215244.html Faron Pharma right in middle of fight against cancer and coronavirus https://www.biotech-capital.com/companies/news/215244/faron-pharma-right-in-middle-of-fight-against-cancer-and-coronavirus-215244.html Fri, 23 Oct 2020 10:30:00 +0100 https://www.biotech-capital.com/companies/news/932150/kazia-therapeutics-completes-252-million-capital-raising-932150.html Kazia Therapeutics completes $25.2 million capital raising https://www.biotech-capital.com/companies/news/932150/kazia-therapeutics-completes-252-million-capital-raising-932150.html Thu, 22 Oct 2020 22:15:00 +0100 https://www.biotech-capital.com/companies/news/932185/avalon-globocare-and-adial-pharmaceuticals-form-strategic-collaboration-to-distribute-covid-19-point-of-care-antibody-rapid-test-devices-932185.html Avalon GloboCare and Adial Pharmaceuticals form strategic collaboration to distribute COVID-19 point-of-care antibody rapid test devices https://www.biotech-capital.com/companies/news/932185/avalon-globocare-and-adial-pharmaceuticals-form-strategic-collaboration-to-distribute-covid-19-point-of-care-antibody-rapid-test-devices-932185.html Thu, 22 Oct 2020 15:35:00 +0100 https://www.biotech-capital.com/companies/news/932172/tetra-bio-pharma-inks-research-deal-to-study-ards-003-in-coronavirus-animal-model-932172.html Tetra Bio-Pharma inks research deal to study ARDS-003 in coronavirus animal model https://www.biotech-capital.com/companies/news/932172/tetra-bio-pharma-inks-research-deal-to-study-ards-003-in-coronavirus-animal-model-932172.html Thu, 22 Oct 2020 14:25:00 +0100 https://www.biotech-capital.com/companies/news/932133/futura-medical-up-almost-a-fifth-after-it-says-it-is-making-commercial-and-regulatory-headway-932133.html Futura Medical up almost a fifth after it says it is making commercial and regulatory headway https://www.biotech-capital.com/companies/news/932133/futura-medical-up-almost-a-fifth-after-it-says-it-is-making-commercial-and-regulatory-headway-932133.html Thu, 22 Oct 2020 14:23:00 +0100 https://www.biotech-capital.com/companies/news/932171/cytodyn-taps-mahboob-rahman-as-chief-scientific-officer-as-it-accelerates-its-clinical-and-regulatory-priorities-932171.html CytoDyn taps Mahboob Rahman as chief scientific officer as it accelerates its clinical and regulatory priorities https://www.biotech-capital.com/companies/news/932171/cytodyn-taps-mahboob-rahman-as-chief-scientific-officer-as-it-accelerates-its-clinical-and-regulatory-priorities-932171.html Thu, 22 Oct 2020 14:15:00 +0100 https://www.biotech-capital.com/companies/news/932119/genedrive-plc-unveils-15-minute-covid-19-point-of-care-test-direct-from-saliva-932119.html genedrive PLC unveils 15-minute COVID-19 point-of-care test direct from saliva https://www.biotech-capital.com/companies/news/932119/genedrive-plc-unveils-15-minute-covid-19-point-of-care-test-direct-from-saliva-932119.html Thu, 22 Oct 2020 13:42:00 +0100 https://www.biotech-capital.com/companies/news/909738/futura-medical-hails-positive-regulatory-momentum-909738.html Futura Medical hails positive regulatory momentum https://www.biotech-capital.com/companies/news/909738/futura-medical-hails-positive-regulatory-momentum-909738.html Thu, 22 Oct 2020 12:18:00 +0100 https://www.biotech-capital.com/companies/news/214099/ixico-cheers-after-fourth-consecutive-year-of-strong-top-line-growth-214099.html IXICO cheers after fourth consecutive year of strong top-line growth https://www.biotech-capital.com/companies/news/214099/ixico-cheers-after-fourth-consecutive-year-of-strong-top-line-growth-214099.html Thu, 22 Oct 2020 10:55:00 +0100 https://www.biotech-capital.com/companies/news/220864/genedrive-enjoys-strong-momentum-with-coronavirus-tests-220864.html Genedrive enjoys strong momentum with coronavirus tests https://www.biotech-capital.com/companies/news/220864/genedrive-enjoys-strong-momentum-with-coronavirus-tests-220864.html Thu, 22 Oct 2020 10:54:00 +0100 https://www.biotech-capital.com/companies/news/932116/ixico-secures-new-contracts-in-huntington-s-disease-clinical-trials-932116.html IXICO secures new contracts in Huntington's disease clinical trials https://www.biotech-capital.com/companies/news/932116/ixico-secures-new-contracts-in-huntington-s-disease-clinical-trials-932116.html Thu, 22 Oct 2020 10:10:00 +0100 https://www.biotech-capital.com/companies/news/932126/4d-pharma-secures-additional-access-to-funds-through-merger-with-longevity-acquisition-corp-932126.html 4D pharma secures additional access to funds through merger with Longevity Acquisition Corp https://www.biotech-capital.com/companies/news/932126/4d-pharma-secures-additional-access-to-funds-through-merger-with-longevity-acquisition-corp-932126.html Thu, 22 Oct 2020 08:02:00 +0100 https://www.biotech-capital.com/companies/news/932108/imugene-progresses-towards-human-studies-for-pd1-vaxx-treatment-by-the-end-of-2020-932108.html Imugene progresses towards human studies for PD1-Vaxx treatment by the end of 2020 https://www.biotech-capital.com/companies/news/932108/imugene-progresses-towards-human-studies-for-pd1-vaxx-treatment-by-the-end-of-2020-932108.html Thu, 22 Oct 2020 06:48:00 +0100 https://www.biotech-capital.com/companies/news/932065/open-orphan-moves-forward-with-government-backed-covid-19-vaccine-human-challenge-study-932065.html Open Orphan moves forward with government-backed COVID-19 vaccine human challenge study https://www.biotech-capital.com/companies/news/932065/open-orphan-moves-forward-with-government-backed-covid-19-vaccine-human-challenge-study-932065.html Wed, 21 Oct 2020 15:43:00 +0100 https://www.biotech-capital.com/companies/news/932052/biocept-announces-appointment-of-molecular-diagnostics-industry-veteran-samuel-d-riccitelli-to-its-board-of-directors-932052.html Biocept announces appointment of molecular diagnostics industry veteran, Samuel D. Riccitelli to its board of directors https://www.biotech-capital.com/companies/news/932052/biocept-announces-appointment-of-molecular-diagnostics-industry-veteran-samuel-d-riccitelli-to-its-board-of-directors-932052.html Wed, 21 Oct 2020 14:30:00 +0100 https://www.biotech-capital.com/companies/news/932042/lexaria-bioscience-wins-first-european-patent-related-to-its-dehydratech-technology-932042.html Lexaria Bioscience wins first European patent related to its DehydraTECH technology https://www.biotech-capital.com/companies/news/932042/lexaria-bioscience-wins-first-european-patent-related-to-its-dehydratech-technology-932042.html Wed, 21 Oct 2020 13:42:00 +0100 https://www.biotech-capital.com/companies/news/218067/alliance-pharma-eyes-pick-up-in-momentum-in-second-half-of-2020-218067.html Alliance Pharma eyes pick up in momentum in second half of 2020 https://www.biotech-capital.com/companies/news/218067/alliance-pharma-eyes-pick-up-in-momentum-in-second-half-of-2020-218067.html Wed, 21 Oct 2020 12:59:00 +0100 https://www.biotech-capital.com/companies/news/932006/oncimmune-welcomes-independent-validation-of-its-lung-blood-test-932006.html Oncimmune welcomes independent validation of its lung blood test https://www.biotech-capital.com/companies/news/932006/oncimmune-welcomes-independent-validation-of-its-lung-blood-test-932006.html Wed, 21 Oct 2020 08:12:00 +0100 https://www.biotech-capital.com/companies/news/931987/kazia-therapeutics-has-a-laser-like-focus-on-adding-value-corporate-connect-research-931987.html Kazia Therapeutics has a laser-like focus on adding value: Corporate Connect Research https://www.biotech-capital.com/companies/news/931987/kazia-therapeutics-has-a-laser-like-focus-on-adding-value-corporate-connect-research-931987.html Wed, 21 Oct 2020 05:45:00 +0100 https://www.biotech-capital.com/companies/news/931982/emyria-in-global-partnership-with-sapphire-medical-clinics-to-leverage-uk-clinical-and-research-expertise-931982.html Emyria in global partnership with Sapphire Medical Clinics to leverage UK clinical and research expertise https://www.biotech-capital.com/companies/news/931982/emyria-in-global-partnership-with-sapphire-medical-clinics-to-leverage-uk-clinical-and-research-expertise-931982.html Wed, 21 Oct 2020 05:05:00 +0100 https://www.biotech-capital.com/companies/news/931979/cellmid-renews-board-to-align-with-consumer-health-growth-strategy-931979.html Cellmid renews board to align with consumer health growth strategy https://www.biotech-capital.com/companies/news/931979/cellmid-renews-board-to-align-with-consumer-health-growth-strategy-931979.html Wed, 21 Oct 2020 04:57:00 +0100 https://www.biotech-capital.com/companies/news/931958/bioasis-technologies-secures-us-patent-for-its-xb3-blood-brain-barrier-drug-delivery-platform-931958.html Bioasis Technologies secures US patent for its xB3 blood-brain barrier drug delivery platform https://www.biotech-capital.com/companies/news/931958/bioasis-technologies-secures-us-patent-for-its-xb3-blood-brain-barrier-drug-delivery-platform-931958.html Tue, 20 Oct 2020 21:51:00 +0100 https://www.biotech-capital.com/companies/news/931948/bioporto-diagnostics-as-is-helping-develop-a-ten-minute-coronavirus-test-that-could-be-on-the-market-by-the-year-end-931948.html BioPorto Diagnostics A/S is helping develop a ten-minute coronavirus test that could be on the market by the year-end https://www.biotech-capital.com/companies/news/931948/bioporto-diagnostics-as-is-helping-develop-a-ten-minute-coronavirus-test-that-could-be-on-the-market-by-the-year-end-931948.html Tue, 20 Oct 2020 17:44:00 +0100 https://www.biotech-capital.com/companies/news/931944/a-covid-vaccine-is-still-months-away-meet-the-companies-preparing-to-wage-war-against-the-coronavirus-931944.html A Covid vaccine is still months away; meet the companies preparing to wage war against the coronavirus https://www.biotech-capital.com/companies/news/931944/a-covid-vaccine-is-still-months-away-meet-the-companies-preparing-to-wage-war-against-the-coronavirus-931944.html Tue, 20 Oct 2020 16:59:00 +0100 https://www.biotech-capital.com/companies/news/931936/cardiol-therapeutics-releases-thc-free-cbd-oil-cortalex-through-shoppers-drug-marts-online-portal-931936.html Cardiol Therapeutics releases THC-free CBD oil Cortalex through Shoppers Drug Mart’s online portal https://www.biotech-capital.com/companies/news/931936/cardiol-therapeutics-releases-thc-free-cbd-oil-cortalex-through-shoppers-drug-marts-online-portal-931936.html Tue, 20 Oct 2020 16:32:00 +0100 https://www.biotech-capital.com/companies/news/931933/skinbiotherapeutics-looks-forward-to-first-revenues-in-2021-931933.html SkinBioTherapeutics looks forward to first revenues in 2021 https://www.biotech-capital.com/companies/news/931933/skinbiotherapeutics-looks-forward-to-first-revenues-in-2021-931933.html Tue, 20 Oct 2020 15:36:00 +0100 https://www.biotech-capital.com/companies/news/927503/the-runners-in-the-covid-19-vaccine-race-927503.html The runners in the COVID-19 vaccine race https://www.biotech-capital.com/companies/news/927503/the-runners-in-the-covid-19-vaccine-race-927503.html Tue, 20 Oct 2020 15:34:00 +0100 https://www.biotech-capital.com/companies/news/931914/revive-therapeutics-signs-supply-agreement-with-havn-life-sciences-to-source-psychedelic-compounds-for-use-in-future-studies-931914.html Revive Therapeutics signs supply agreement with Havn Life Sciences to source psychedelic compounds for use in future studies https://www.biotech-capital.com/companies/news/931914/revive-therapeutics-signs-supply-agreement-with-havn-life-sciences-to-source-psychedelic-compounds-for-use-in-future-studies-931914.html Tue, 20 Oct 2020 14:17:00 +0100 https://www.biotech-capital.com/companies/news/931911/tetra-bio-pharma-releases-positive-results-for-ards-003-in-animal-studies-for-treating-inflammatory-lung-injury-931911.html Tetra Bio-Pharma releases positive results for ARDS-003 in animal studies for treating inflammatory lung injury https://www.biotech-capital.com/companies/news/931911/tetra-bio-pharma-releases-positive-results-for-ards-003-in-animal-studies-for-treating-inflammatory-lung-injury-931911.html Tue, 20 Oct 2020 13:49:00 +0100 https://www.biotech-capital.com/companies/news/931904/cytodyn-wins-positive-dsmc-recommendation-after-interim-analysis-of-leronlimab-in-phase-2b3-covid-19-trial-931904.html CytoDyn wins positive DSMC recommendation after interim analysis of leronlimab in Phase 2b/3 COVID-19 trial https://www.biotech-capital.com/companies/news/931904/cytodyn-wins-positive-dsmc-recommendation-after-interim-analysis-of-leronlimab-in-phase-2b3-covid-19-trial-931904.html Tue, 20 Oct 2020 13:18:00 +0100 https://www.biotech-capital.com/companies/news/931887/arecor-and-hikma-expand-collaboration-to-second-product-931887.html Arecor and Hikma expand collaboration to second product https://www.biotech-capital.com/companies/news/931887/arecor-and-hikma-expand-collaboration-to-second-product-931887.html Tue, 20 Oct 2020 09:31:00 +0100 https://www.biotech-capital.com/companies/news/931865/open-orphan-says-hvivo-unit-secures-multi-million-pound-uk-government-covid-19-contract-931865.html Open Orphan says hVIVO unit secures multi-million pound UK government COVID-19 contract https://www.biotech-capital.com/companies/news/931865/open-orphan-says-hvivo-unit-secures-multi-million-pound-uk-government-covid-19-contract-931865.html Tue, 20 Oct 2020 07:56:00 +0100 https://www.biotech-capital.com/companies/news/931866/astrazeneca-says-tagrisso-granted-priority-review-in-us-931866.html AstraZeneca says Tagrisso granted priority review in US https://www.biotech-capital.com/companies/news/931866/astrazeneca-says-tagrisso-granted-priority-review-in-us-931866.html Tue, 20 Oct 2020 07:54:00 +0100 https://www.biotech-capital.com/companies/news/931863/collagen-solutions-says-offer-from-rosen-s-is-now-wholly-unconditional-931863.html Collagen Solutions says offer from Rosen's is now wholly unconditional https://www.biotech-capital.com/companies/news/931863/collagen-solutions-says-offer-from-rosen-s-is-now-wholly-unconditional-931863.html Tue, 20 Oct 2020 07:48:00 +0100 https://www.biotech-capital.com/companies/news/931855/angle-liquid-biopsy-moves-into-the-crucial-final-phase-of-regulatory-scrutiny-as-it-seeks-clearance-from-us-food--drug-administration-931855.html ANGLE liquid biopsy moves into the crucial final phase of regulatory scrutiny as it seeks clearance from US Food & Drug Administration https://www.biotech-capital.com/companies/news/931855/angle-liquid-biopsy-moves-into-the-crucial-final-phase-of-regulatory-scrutiny-as-it-seeks-clearance-from-us-food--drug-administration-931855.html Tue, 20 Oct 2020 07:26:00 +0100 https://www.biotech-capital.com/companies/news/931783/us-stocks-close-sharply-lower-as-coronavirus-deal-deadline-looms-931783.html US stocks close sharply lower as coronavirus deal deadline looms https://www.biotech-capital.com/companies/news/931783/us-stocks-close-sharply-lower-as-coronavirus-deal-deadline-looms-931783.html Mon, 19 Oct 2020 21:10:00 +0100 https://www.biotech-capital.com/companies/news/931804/orgenesis-completes-acquisition-of-koligo-therapeutics-and-acquires-assets-of-tissue-genesis-llc-931804.html Orgenesis completes acquisition of Koligo Therapeutics and acquires assets of Tissue Genesis LLC https://www.biotech-capital.com/companies/news/931804/orgenesis-completes-acquisition-of-koligo-therapeutics-and-acquires-assets-of-tissue-genesis-llc-931804.html Mon, 19 Oct 2020 15:30:00 +0100 https://www.biotech-capital.com/companies/news/931798/matinas-biopharma-s-cryptococcal-meningitis-trial-of-mat2203-gets-approval-from-oversight-board-after-first-cohort-931798.html Matinas BioPharma's cryptococcal meningitis trial of MAT2203 gets approval from oversight board after first cohort https://www.biotech-capital.com/companies/news/931798/matinas-biopharma-s-cryptococcal-meningitis-trial-of-mat2203-gets-approval-from-oversight-board-after-first-cohort-931798.html Mon, 19 Oct 2020 14:56:00 +0100 https://www.biotech-capital.com/companies/news/931793/aequus-and-partner-medicom-healthcare-win-medical-device-license-for-evolve-intensive-gel-to-treat-dry-eye-disease-931793.html Aequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye Disease https://www.biotech-capital.com/companies/news/931793/aequus-and-partner-medicom-healthcare-win-medical-device-license-for-evolve-intensive-gel-to-treat-dry-eye-disease-931793.html Mon, 19 Oct 2020 14:33:00 +0100 https://www.biotech-capital.com/companies/news/931796/betterlife-pharma--launchesmarketed-private-placement-offering-of-special-warrants-for-gross-proceeds-of-up-to-5-million-931796.html BetterLife Pharma launches marketed private placement offering of special warrants for gross proceeds of up to $5 million https://www.biotech-capital.com/companies/news/931796/betterlife-pharma--launchesmarketed-private-placement-offering-of-special-warrants-for-gross-proceeds-of-up-to-5-million-931796.html Mon, 19 Oct 2020 14:25:00 +0100 https://www.biotech-capital.com/companies/news/931791/xphyto-german-subsidiary-vektor-pharma-builds-oral-disintegrating-film-formulation-for-big-european-client-931791.html XPhyto German subsidiary Vektor Pharma builds oral disintegrating film formulation for big European client https://www.biotech-capital.com/companies/news/931791/xphyto-german-subsidiary-vektor-pharma-builds-oral-disintegrating-film-formulation-for-big-european-client-931791.html Mon, 19 Oct 2020 14:05:00 +0100 https://www.biotech-capital.com/companies/news/931777/pfizer-hopes-to-produce-100mln-covid-19-vaccine-doses-before-2021-931777.html Pfizer hopes to produce 100mln COVID-19 vaccine doses before 2021 https://www.biotech-capital.com/companies/news/931777/pfizer-hopes-to-produce-100mln-covid-19-vaccine-doses-before-2021-931777.html Mon, 19 Oct 2020 11:56:00 +0100 https://www.biotech-capital.com/companies/news/921600/incanthera-eyes-huge-market-for-cancer-prevention-suncream-921600.html Incanthera eyes huge market for cancer-prevention suncream https://www.biotech-capital.com/companies/news/921600/incanthera-eyes-huge-market-for-cancer-prevention-suncream-921600.html Mon, 19 Oct 2020 10:12:00 +0100 https://www.biotech-capital.com/companies/news/931744/astrazeneca-receives-recommendation-for-approval-for-two-candidates-from-eu-committee-931744.html AstraZeneca receives recommendation for approval for two candidates from EU committee https://www.biotech-capital.com/companies/news/931744/astrazeneca-receives-recommendation-for-approval-for-two-candidates-from-eu-committee-931744.html Mon, 19 Oct 2020 07:55:00 +0100 https://www.biotech-capital.com/companies/news/931748/amryt-pharma-inks-distribution-deal-covering-central-and-eastern-europe-with-swiss-partner-931748.html Amryt Pharma inks distribution deal covering central and eastern Europe with Swiss partner https://www.biotech-capital.com/companies/news/931748/amryt-pharma-inks-distribution-deal-covering-central-and-eastern-europe-with-swiss-partner-931748.html Mon, 19 Oct 2020 07:54:00 +0100 https://www.biotech-capital.com/companies/news/931737/ixico-sees-full-year-underlying-earnings-more-than-double-in-fourth-consecutive-year-of-strong-top-line-growth-931737.html IXICO sees full-year underlying earnings more than double in fourth consecutive year of strong top-line growth https://www.biotech-capital.com/companies/news/931737/ixico-sees-full-year-underlying-earnings-more-than-double-in-fourth-consecutive-year-of-strong-top-line-growth-931737.html Mon, 19 Oct 2020 07:30:00 +0100 https://www.biotech-capital.com/companies/news/931735/shield-therapeutics-says-teva-has-withdrawn-patent-challenge-931735.html Shield Therapeutics says TEVA has withdrawn patent challenge https://www.biotech-capital.com/companies/news/931735/shield-therapeutics-says-teva-has-withdrawn-patent-challenge-931735.html Mon, 19 Oct 2020 07:19:00 +0100 https://www.biotech-capital.com/companies/news/931683/naturally-splendid-answers-health-canada-questions-in-progress-toward-phase-2-coronavirus-trial-of-cavaltinib-931683.html Naturally Splendid answers Health Canada questions in progress toward Phase 2 coronavirus trial of cavaltinib https://www.biotech-capital.com/companies/news/931683/naturally-splendid-answers-health-canada-questions-in-progress-toward-phase-2-coronavirus-trial-of-cavaltinib-931683.html Fri, 16 Oct 2020 15:04:00 +0100 https://www.biotech-capital.com/companies/news/931679/calyxt-announces-15m-registered-direct-offering-to-advance-its-product-development-pipeline-and-talen-technology-931679.html Calyxt announces $15M registered direct offering to advance its product development pipeline and TALEN technology https://www.biotech-capital.com/companies/news/931679/calyxt-announces-15m-registered-direct-offering-to-advance-its-product-development-pipeline-and-talen-technology-931679.html Fri, 16 Oct 2020 14:51:00 +0100 https://www.biotech-capital.com/companies/news/931678/aequus-extends-commercial-agreement-with-sandoz-for-transplant-therapy-tacrolimus-in-canada-931678.html Aequus extends commercial agreement with Sandoz for transplant therapy tacrolimus in Canada https://www.biotech-capital.com/companies/news/931678/aequus-extends-commercial-agreement-with-sandoz-for-transplant-therapy-tacrolimus-in-canada-931678.html Fri, 16 Oct 2020 14:39:00 +0100 https://www.biotech-capital.com/companies/news/220929/iq-ai-s-imaging-biometrics-at-the-forefront-of-brain-tumour-analysis-220929.html IQ-AI's Imaging Biometrics at the forefront of brain tumour analysis https://www.biotech-capital.com/companies/news/220929/iq-ai-s-imaging-biometrics-at-the-forefront-of-brain-tumour-analysis-220929.html Fri, 16 Oct 2020 14:18:00 +0100 https://www.biotech-capital.com/companies/news/903476/amryt-pharma-cheers-orphan-designation-for-pre-clinical-skin-treatment-903476.html Amryt Pharma cheers orphan designation for pre-clinical skin treatment https://www.biotech-capital.com/companies/news/903476/amryt-pharma-cheers-orphan-designation-for-pre-clinical-skin-treatment-903476.html Fri, 16 Oct 2020 14:17:00 +0100 https://www.biotech-capital.com/companies/news/931674/volitionrx-to-present-canine-cancer-detection-studies-of-its-nuq-vet-cancer-screening-test-at-veterinary-conference-this-week-931674.html VolitionRx to present canine cancer detection studies of its Nu.Q Vet Cancer Screening Test at veterinary conference this week https://www.biotech-capital.com/companies/news/931674/volitionrx-to-present-canine-cancer-detection-studies-of-its-nuq-vet-cancer-screening-test-at-veterinary-conference-this-week-931674.html Fri, 16 Oct 2020 14:08:00 +0100 https://www.biotech-capital.com/companies/news/931675/synairgen-gets-house-broker-upgrade-after-impressive-fundraise-931675.html Synairgen gets house broker upgrade after impressive fundraise https://www.biotech-capital.com/companies/news/931675/synairgen-gets-house-broker-upgrade-after-impressive-fundraise-931675.html Fri, 16 Oct 2020 14:03:00 +0100 https://www.biotech-capital.com/companies/news/931656/faron-pharma-says-disappointed-but-not-surprised-by-who-coronavirus-trial-data-931656.html Faron Pharma says disappointed but not surprised by WHO coronavirus trial data https://www.biotech-capital.com/companies/news/931656/faron-pharma-says-disappointed-but-not-surprised-by-who-coronavirus-trial-data-931656.html Fri, 16 Oct 2020 12:19:00 +0100 https://www.biotech-capital.com/companies/news/931625/scancell-is-cashed-up-and-looking-to-extend-its-capabilities-931625.html Scancell is cashed up and looking to extend its capabilities https://www.biotech-capital.com/companies/news/931625/scancell-is-cashed-up-and-looking-to-extend-its-capabilities-931625.html Fri, 16 Oct 2020 07:41:00 +0100 https://www.biotech-capital.com/companies/news/931602/kazia-therapeutics-executes-agreement-to-begin-gbm-agile-pivotal-study-931602.html Kazia Therapeutics executes agreement to begin GBM Agile pivotal study https://www.biotech-capital.com/companies/news/931602/kazia-therapeutics-executes-agreement-to-begin-gbm-agile-pivotal-study-931602.html Fri, 16 Oct 2020 00:15:00 +0100 https://www.biotech-capital.com/companies/news/931601/zynerba-to-present-fragile-x-connect-fx-study-data-at-virtual-child-neurology-events-931601.html Zynerba to present Fragile X CONNECT-FX study data at virtual child neurology events https://www.biotech-capital.com/companies/news/931601/zynerba-to-present-fragile-x-connect-fx-study-data-at-virtual-child-neurology-events-931601.html Thu, 15 Oct 2020 21:51:00 +0100 https://www.biotech-capital.com/companies/news/931568/betterlife-pharma-chooses-contract-research-organization-for-australia-coronavirus-trial-of-ap-003-931568.html BetterLife Pharma chooses contract research organization for Australia coronavirus trial of AP-003 https://www.biotech-capital.com/companies/news/931568/betterlife-pharma-chooses-contract-research-organization-for-australia-coronavirus-trial-of-ap-003-931568.html Thu, 15 Oct 2020 15:05:00 +0100 https://www.biotech-capital.com/companies/news/931502/synairgen-successfully-closes-80mln-share-sale-to-fund-pivotal-trial-and-manufacturing-of-breakthrough-covid-19-drug-931502.html Synairgen successfully closes £80mln share sale to fund pivotal trial and manufacturing of breakthrough COVID-19 drug https://www.biotech-capital.com/companies/news/931502/synairgen-successfully-closes-80mln-share-sale-to-fund-pivotal-trial-and-manufacturing-of-breakthrough-covid-19-drug-931502.html Thu, 15 Oct 2020 07:32:00 +0100 https://www.biotech-capital.com/companies/news/931448/heritage-cannabis-holdings-corp-appoints-umar-syed-as-president-medical-products-role-931448.html Heritage Cannabis Holdings Corp appoints Umar Syed as president medical products role https://www.biotech-capital.com/companies/news/931448/heritage-cannabis-holdings-corp-appoints-umar-syed-as-president-medical-products-role-931448.html Wed, 14 Oct 2020 14:05:00 +0100 https://www.biotech-capital.com/companies/news/931405/4d-pharma-says-cancer-conference-provides-forum-for-update-on-lead-drug-931405.html 4D pharma says cancer conference provides forum for update on lead drug https://www.biotech-capital.com/companies/news/931405/4d-pharma-says-cancer-conference-provides-forum-for-update-on-lead-drug-931405.html Wed, 14 Oct 2020 08:01:00 +0100 https://www.biotech-capital.com/companies/news/931397/skinbiotherapeutics-raises-4mln-to-accelerate-development-931397.html SkinBioTherapeutics raises £4mln to accelerate development https://www.biotech-capital.com/companies/news/931397/skinbiotherapeutics-raises-4mln-to-accelerate-development-931397.html Wed, 14 Oct 2020 07:37:00 +0100 https://www.biotech-capital.com/companies/news/931391/kazia-therapeutics-directors-support-company-through-entitlement-offer-participation-931391.html Kazia Therapeutics directors support company through entitlement offer participation https://www.biotech-capital.com/companies/news/931391/kazia-therapeutics-directors-support-company-through-entitlement-offer-participation-931391.html Wed, 14 Oct 2020 07:22:00 +0100 https://www.biotech-capital.com/companies/news/931380/pharmaxis-receives-5-million-rd-tax-incentive-as-it-progresses-myelofibrosis-treatment-931380.html Pharmaxis receives $5 million R&D tax incentive as it progresses myelofibrosis treatment https://www.biotech-capital.com/companies/news/931380/pharmaxis-receives-5-million-rd-tax-incentive-as-it-progresses-myelofibrosis-treatment-931380.html Wed, 14 Oct 2020 04:08:00 +0100 https://www.biotech-capital.com/companies/news/931376/spasx-200-dips-below-flatline-as-miners-and-banks-weigh-the-market-down-931376.html S&P/ASX 200 dips below flatline as miners and banks weigh the market down https://www.biotech-capital.com/companies/news/931376/spasx-200-dips-below-flatline-as-miners-and-banks-weigh-the-market-down-931376.html Wed, 14 Oct 2020 03:41:00 +0100 https://www.biotech-capital.com/companies/news/931263/emyria-uniquely-positioned-to-take-the-lead-in-future-of-medicine-as-it-moves-beyond-clinics-931263.html Emyria uniquely positioned to take the lead in future of medicine as it moves beyond clinics https://www.biotech-capital.com/companies/news/931263/emyria-uniquely-positioned-to-take-the-lead-in-future-of-medicine-as-it-moves-beyond-clinics-931263.html Tue, 13 Oct 2020 22:58:00 +0100 https://www.biotech-capital.com/companies/news/931350/milestone-scientific-wins-group-purchasing-deal-for-compuflo-epidural-system-and-cathcheck-931350.html Milestone Scientific wins group purchasing deal for CompuFlo Epidural System and CathCheck https://www.biotech-capital.com/companies/news/931350/milestone-scientific-wins-group-purchasing-deal-for-compuflo-epidural-system-and-cathcheck-931350.html Tue, 13 Oct 2020 16:24:00 +0100 https://www.biotech-capital.com/companies/news/931340/aim-immunotech-is-developing-immuno-therapeutics-to-treat-multiple-types-of-cancers-and-fighting-coronavirus-too-931340.html AIM ImmunoTech is developing immuno-therapeutics to treat multiple types of cancers and fighting coronavirus too https://www.biotech-capital.com/companies/news/931340/aim-immunotech-is-developing-immuno-therapeutics-to-treat-multiple-types-of-cancers-and-fighting-coronavirus-too-931340.html Tue, 13 Oct 2020 15:15:00 +0100 https://www.biotech-capital.com/companies/news/931325/algernon-announces-25-enrollment-for-its-phase-2-idiopathic-pulmonary-fibrosis-and-chronic-cough-study-of-ifenprodil-931325.html Algernon announces 25% enrollment for its Phase 2 idiopathic pulmonary fibrosis and chronic cough study of Ifenprodil https://www.biotech-capital.com/companies/news/931325/algernon-announces-25-enrollment-for-its-phase-2-idiopathic-pulmonary-fibrosis-and-chronic-cough-study-of-ifenprodil-931325.html Tue, 13 Oct 2020 14:15:00 +0100 https://www.biotech-capital.com/companies/news/931318/valeo-pharma-commences-shipping-online-orders-for-its-hesperco-immune-support-capsules-931318.html Valeo Pharma commences shipping online orders for its Hesperco immune support capsules https://www.biotech-capital.com/companies/news/931318/valeo-pharma-commences-shipping-online-orders-for-its-hesperco-immune-support-capsules-931318.html Tue, 13 Oct 2020 13:29:00 +0100 https://www.biotech-capital.com/companies/news/931317/johnson--johnson-second-on-the-list-of-covid-19-vaccine-setbacks-markets-remain-calm-931317.html Johnson & Johnson second on the list of COVID-19 vaccine setbacks, markets remain calm https://www.biotech-capital.com/companies/news/931317/johnson--johnson-second-on-the-list-of-covid-19-vaccine-setbacks-markets-remain-calm-931317.html Tue, 13 Oct 2020 13:13:00 +0100 https://www.biotech-capital.com/companies/news/931313/cytodyn-taps-chiral-pharma-to-win-local-approval-for-leronlimab-in-the-philippines-931313.html CytoDyn taps Chiral Pharma to win local approval for leronlimab in the Philippines https://www.biotech-capital.com/companies/news/931313/cytodyn-taps-chiral-pharma-to-win-local-approval-for-leronlimab-in-the-philippines-931313.html Tue, 13 Oct 2020 12:50:00 +0100 https://www.biotech-capital.com/companies/news/931282/sareum-says-progress-has-been-good-across-a-range-of-programmes-931282.html Sareum says progress has been good across a range of programmes https://www.biotech-capital.com/companies/news/931282/sareum-says-progress-has-been-good-across-a-range-of-programmes-931282.html Tue, 13 Oct 2020 07:46:00 +0100 https://www.biotech-capital.com/companies/news/931274/oncimmune-links-up-with-world-renowned-cedars-sinai-for-covid-19-programme-931274.html Oncimmune links up with world-renowned Cedars-Sinai for COVID-19 programme https://www.biotech-capital.com/companies/news/931274/oncimmune-links-up-with-world-renowned-cedars-sinai-for-covid-19-programme-931274.html Tue, 13 Oct 2020 07:45:00 +0100 https://www.biotech-capital.com/companies/news/931266/growing-maxcyte-bolsters-leadership-team-with-three-senior-appointments-931266.html Growing MaxCyte bolsters leadership team with three senior appointments https://www.biotech-capital.com/companies/news/931266/growing-maxcyte-bolsters-leadership-team-with-three-senior-appointments-931266.html Tue, 13 Oct 2020 07:26:00 +0100 https://www.biotech-capital.com/companies/news/931256/spasx-200-hits-seven-month-high-following-another-improvement-on-wall-street-931256.html S&P/ASX 200 hits seven-month high following another improvement on Wall Street https://www.biotech-capital.com/companies/news/931256/spasx-200-hits-seven-month-high-following-another-improvement-on-wall-street-931256.html Tue, 13 Oct 2020 03:40:00 +0100 https://www.biotech-capital.com/companies/news/931244/paradigm-biopharmaceuticals-adds-three-new-senior-executives-to-its-team-931244.html Paradigm Biopharmaceuticals adds three new senior executives to its team https://www.biotech-capital.com/companies/news/931244/paradigm-biopharmaceuticals-adds-three-new-senior-executives-to-its-team-931244.html Tue, 13 Oct 2020 00:32:00 +0100 https://www.biotech-capital.com/companies/news/220600/scancell-focuses-on-cancer-immunotherapies-and-covid-19-vaccine-220600.html Scancell focuses on cancer immunotherapies and COVID-19 vaccine https://www.biotech-capital.com/companies/news/220600/scancell-focuses-on-cancer-immunotherapies-and-covid-19-vaccine-220600.html Mon, 12 Oct 2020 14:47:00 +0100 https://www.biotech-capital.com/companies/news/931138/fsd-pharma-throws-resources-behind-legacy-anti-inflammatory-drug-as-potential-coronavirus-therapy-931138.html FSD Pharma throws resources behind legacy anti-inflammatory drug as potential coronavirus therapy https://www.biotech-capital.com/companies/news/931138/fsd-pharma-throws-resources-behind-legacy-anti-inflammatory-drug-as-potential-coronavirus-therapy-931138.html Mon, 12 Oct 2020 14:15:00 +0100 https://www.biotech-capital.com/companies/news/931232/dyadic-makes-swift-progress-as-its-c1-protein-manufacturing-platform-is-used-for-covid-19-initiatives-931232.html Dyadic makes swift progress as its C1 protein manufacturing platform is used for COVID-19 initiatives https://www.biotech-capital.com/companies/news/931232/dyadic-makes-swift-progress-as-its-c1-protein-manufacturing-platform-is-used-for-covid-19-initiatives-931232.html Mon, 12 Oct 2020 13:08:00 +0100 https://www.biotech-capital.com/companies/news/931153/antibes-breakthrough-osteoarthritis-pain-relief-drug-in-the-spotlight-on-world-arthritis-day-931153.html Antibe’s breakthrough osteoarthritis pain relief drug in the spotlight on World Arthritis Day https://www.biotech-capital.com/companies/news/931153/antibes-breakthrough-osteoarthritis-pain-relief-drug-in-the-spotlight-on-world-arthritis-day-931153.html Mon, 12 Oct 2020 12:30:00 +0100 https://www.biotech-capital.com/companies/news/931185/scancell-raises-30mln-to-advance-growing-pipeline-of-cancer-immunotherapies-and-covid-19-vaccine-931185.html Scancell raises £30mln to advance growing pipeline of cancer immunotherapies and COVID-19 vaccine https://www.biotech-capital.com/companies/news/931185/scancell-raises-30mln-to-advance-growing-pipeline-of-cancer-immunotherapies-and-covid-19-vaccine-931185.html Mon, 12 Oct 2020 08:12:00 +0100 https://www.biotech-capital.com/companies/news/931183/e-therapeutics-re-energised-as-executive-chairman-mortazavi-takes-over-ceo-duties-931183.html e-therapeutics re-energised as executive chairman Mortazavi takes over CEO duties https://www.biotech-capital.com/companies/news/931183/e-therapeutics-re-energised-as-executive-chairman-mortazavi-takes-over-ceo-duties-931183.html Mon, 12 Oct 2020 08:03:00 +0100 https://www.biotech-capital.com/companies/news/931175/astrazeneca-to-begin-late-stage-trials-on-covid-19-antibody-prevention-candidate-931175.html AstraZeneca to begin late-stage trials on COVID-19 antibody prevention candidate https://www.biotech-capital.com/companies/news/931175/astrazeneca-to-begin-late-stage-trials-on-covid-19-antibody-prevention-candidate-931175.html Mon, 12 Oct 2020 07:33:00 +0100 https://www.biotech-capital.com/companies/news/931075/coffee-with-samso-the-business-of-making-gloves---nitrile-gloves-931075.html Coffee with Samso: The business of making gloves - nitrile gloves https://www.biotech-capital.com/companies/news/931075/coffee-with-samso-the-business-of-making-gloves---nitrile-gloves-931075.html Fri, 09 Oct 2020 22:28:00 +0100 https://www.biotech-capital.com/companies/news/931121/mindmed-announces-25m-bought-deal-offering-to-finance-development-of-its-psychedelic-assisted-therapies-and-medicines-931121.html MindMed announces $25M bought-deal offering to finance development of its psychedelic-assisted therapies and medicines https://www.biotech-capital.com/companies/news/931121/mindmed-announces-25m-bought-deal-offering-to-finance-development-of-its-psychedelic-assisted-therapies-and-medicines-931121.html Fri, 09 Oct 2020 14:39:00 +0100 https://www.biotech-capital.com/companies/news/931115/algernon-pharmaceuticals-names-dr-mark-swaim-to-its-medical-and-scientific-advisory-board-931115.html Algernon Pharmaceuticals names Dr Mark Swaim to its medical and scientific advisory board https://www.biotech-capital.com/companies/news/931115/algernon-pharmaceuticals-names-dr-mark-swaim-to-its-medical-and-scientific-advisory-board-931115.html Fri, 09 Oct 2020 13:50:00 +0100 https://www.biotech-capital.com/companies/news/931047/bioasis-has-the-best-platform-technology-for-shuttling-drugs-across-the-blood-brain-barrier-931047.html Bioasis has the best platform technology for shuttling drugs across the blood-brain barrier https://www.biotech-capital.com/companies/news/931047/bioasis-has-the-best-platform-technology-for-shuttling-drugs-across-the-blood-brain-barrier-931047.html Fri, 09 Oct 2020 11:33:00 +0100 https://www.biotech-capital.com/companies/news/931065/anteris-technologies-exceeds-expectations-as-duravr-patient-outcomes-demonstrate-superiority-over-existing-valves-931065.html Anteris Technologies exceeds expectations as DurAVR™ patient outcomes demonstrate superiority over existing valves https://www.biotech-capital.com/companies/news/931065/anteris-technologies-exceeds-expectations-as-duravr-patient-outcomes-demonstrate-superiority-over-existing-valves-931065.html Fri, 09 Oct 2020 04:22:00 +0100 https://www.biotech-capital.com/companies/news/931031/zynerba-says-two-poster-presentations-about-its-cbd-gel-were-accepted-for-a-virtual-child-neurology-conference-931031.html Zynerba says two poster presentations about its CBD gel were accepted for a virtual child neurology conference https://www.biotech-capital.com/companies/news/931031/zynerba-says-two-poster-presentations-about-its-cbd-gel-were-accepted-for-a-virtual-child-neurology-conference-931031.html Thu, 08 Oct 2020 16:25:00 +0100 https://www.biotech-capital.com/companies/news/931034/barclays-sees-ocado-riding-for-a-fall-suggests-seven-uk-top-picks-instead-931034.html Barclays sees Ocado riding for a fall, suggests seven UK top picks instead https://www.biotech-capital.com/companies/news/931034/barclays-sees-ocado-riding-for-a-fall-suggests-seven-uk-top-picks-instead-931034.html Thu, 08 Oct 2020 16:06:00 +0100 https://www.biotech-capital.com/companies/news/931015/betterlife-pharma-announces-virtrial-as-patient-monitoring-partner-for-covid-19-study-in-australia-to-test-efficacy-of-ap-003-931015.html BetterLife Pharma announces VirTrial as patient monitoring partner for COVID-19 study in Australia to test efficacy of AP-003 https://www.biotech-capital.com/companies/news/931015/betterlife-pharma-announces-virtrial-as-patient-monitoring-partner-for-covid-19-study-in-australia-to-test-efficacy-of-ap-003-931015.html Thu, 08 Oct 2020 14:24:00 +0100 https://www.biotech-capital.com/companies/news/931012/willow-biosciences-partners-with-lethbridge-and-calgary-universities-to-study-the-effects-of-non-psychoactive-cannabinoids-on-intestinal-inflammation-abdominal-pain-and-depression-931012.html Willow Biosciences partners with Lethbridge and Calgary universities to study the effects of non-psychoactive cannabinoids on intestinal inflammation, abdominal pain and depression https://www.biotech-capital.com/companies/news/931012/willow-biosciences-partners-with-lethbridge-and-calgary-universities-to-study-the-effects-of-non-psychoactive-cannabinoids-on-intestinal-inflammation-abdominal-pain-and-depression-931012.html Thu, 08 Oct 2020 13:37:00 +0100 https://www.biotech-capital.com/companies/news/930996/liberum-hikes-target-price-for-astrazeneca-on-daiichi-sankyo-collaboration-prospects-930996.html Liberum hikes target price for AstraZeneca on Daiichi Sankyo collaboration prospects https://www.biotech-capital.com/companies/news/930996/liberum-hikes-target-price-for-astrazeneca-on-daiichi-sankyo-collaboration-prospects-930996.html Thu, 08 Oct 2020 11:34:00 +0100 https://www.biotech-capital.com/companies/news/930971/amryt-pharma-to-showcase-data-from-successful-phase-iii-study-at-international-dermatology-conference-930971.html Amryt Pharma to showcase data from successful phase III study at international dermatology conference https://www.biotech-capital.com/companies/news/930971/amryt-pharma-to-showcase-data-from-successful-phase-iii-study-at-international-dermatology-conference-930971.html Thu, 08 Oct 2020 08:11:00 +0100 https://www.biotech-capital.com/companies/news/930964/sareum-holdings-says-it-is-close-to-winning-us-patent-protection-for-cancer-immunotherapy-programme-930964.html Sareum Holdings says it is close to winning US patent protection for cancer immunotherapy programme https://www.biotech-capital.com/companies/news/930964/sareum-holdings-says-it-is-close-to-winning-us-patent-protection-for-cancer-immunotherapy-programme-930964.html Thu, 08 Oct 2020 07:51:00 +0100